VIP and asthma: In addition, M-BYF was also found to alleviate AHR, airway inflammation and remodeling in asthma mice by negatively regulating the vasoactive intestinal peptide-vasoactive intestinal peptide receptor type 2 (VIP-VPAC2) signaling pathway (Huang et al., 2021).